1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2:

Antiplatelet regimen timeline

Observation PeriodInterventionDay 1 after interventionFollow-Up Period
Delivery of the First StentDuring Intervention12:00 am4:00 am10:00 am
ASA 100 mg/dayTirofiban (Aggrastat) i.v.,Multiplate testClopidogrel 300 mg p.o.Tirofiban (Aggrastat) i.v., stoppedMultiplate test1) First 6 months clopidogrel 75 mg/day and ASA 100 mg/day
1) loading dose, 0.4 μg/kg/min (30 min),1) 15 min after tirofiban start,ASA 100 mg p.o.ASA response? clopidogrel response?2) lifelong therapy ASA 100 mg/day
2) maintenance dose, 0.1 μg/kg/min2) end of the intervention, tirofiban response?
  • Note:—p.o. indicates by mouth; i.v., intravenous.